Foley Partner Gardner Davis and Senior Counsel Danielle Whitley authored an article titled “NOL and void” in the April 5, 2010 issue of The Deal. The authors discuss a Delaware Court of Chancery decision that upheld Selectica Inc.’s selection of a shareholder rights plan, or poison pill, as a tool to protect its net operating loss carry forwards (NOLs), remarking that it is the first time that a Delaware court has reviewed a board’s decision to adopt a poison pill intended to guard NOLs. They add that the decision should not be interpreted as support for the suggestion that a board can safely adopt a poison pill in every circumstance, noting the court’s acknowledgment that shareholder rights plans must be subject to careful review.
Author(s)
Related Insights
March 16, 2026
Tariff & International Trade Resource
What Every Multinational Should Know About …Managing the Aftermath of the Supreme Court’s Historic IEEPA Tariff Decision (Part VIII)
In a recent filing before the CIT, CBP described a new capability being developed within the Automated Commercial Environment (ACE) called CAPE (Consolidated Administration and Processing of Entries).
March 16, 2026
Tariff & International Trade Resource
What Every Multinational Should Know About …Managing the Aftermath of the Supreme Court’s Historic IEEPA Tariff Case (Part VII)
The Supreme Court’s ruling rejected IEEPA as a basis for broad tariffs, but it did not call into question tariffs imposed under other trade statutes. That means the decision removed one legal mechanism, not the broader policy goals that drove the tariffs in the first place.
March 16, 2026
Energy Current
One Big Beautiful Bill (“OB3”) and FEOC: Current Considerations for Debt Financings
The One Big Beautiful Bill Act (the “Act”), passed in July 2024, and related recent additional guidance, has created ripple effects…